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Protein conformation in a vaccine matters
Trudy G. Morrison
Vaccination is one of the most successful public 
health measures for control of viral diseases. Indeed, 
vaccines have either eliminated or considerably reduced 
many viral diseases worldwide. However, there are still 
many serious viral pathogens for which no vaccine is 
available. One of these pathogens is respiratory syncytial 
virus (RSV).
RSV is a significant threat to human health. The 
virus is the principle cause of acute viral lower respiratory 
tract infections in infants and young children. RSV 
results in, world wide, 38 million infections per year in 
children under 5 years of age with ten percent of those 
requiring hospitalization and up to 200,000 deaths per 
year [1]. Severe RSV infections during infancy have been 
correlated with the development of asthma in later years. 
In addition, the elderly, immunocompromised populations, 
stem cell transplant recipients, and individuals with 
cardiopulmonary diseases are also at risk for serious, 
potentially life threatening RSV disease [2].
RSV, a paramyxovirus, is an enveloped, negative-
stranded RNA virus. While virions contain three surface 
glycoproteins, G, SH, and F proteins, it is the F protein 
that is considered the antigen that stimulates the most 
potent and broadest spectrum of protective antibodies. The 
paramyxovirus F protein mediates fusion of viral and cell 
membranes important for virus entry into cells. As with all 
paramyxovirus F proteins, the fusion competent molecule 
is folded and assembled into virus in a metastable, pre-
fusion conformation. Upon activation of fusion during 
the onset of infection, the pre-fusion F protein undergoes 
major conformational changes refolding into a biologically 
inactive post fusion form and in the process mediating the 
post-fusion of viral and cellular membranes. 
RSV vaccine development has been ongoing for 
decades without resulting in a licensed vaccine. Previously 
tested vaccine candidates have failed in human trials due 
to their failure to stimulate adequate levels of protective 
immunity. It has recently become clear that many of 
these vaccine candidates have likely failed because they 
contained primarily the post-fusion form of the F protein. 
Recent major advances from several laboratories hold 
promise to accelerate development of a vaccine. Most 
importantly, McLellan, et al solved the structure of the 
particularly unstable pre-fusion RSV F protein, revealed 
a novel antigenic site on the pre-fusion F protein, and, 
furthermore, identified mutations that stabilized the pre-
fusion F protein [3, 4]. While the post-fusion F protein 
can stimulate neutralizing antibodies, these antibodies 
require much higher concentrations to neutralize virus 
than antibodies specific for the novel, pre-fusion F 
protein antigenic site, likely accounting for the failure of 
previously tested vaccine candidates. 
We have recently reported incorporation of these 
stabilizing mutational changes into the RSV F protein 
associated with a virus-like particle (VLP) vaccine 
candidate and demonstrated a significantly improved 
protective response to this vaccine candidate in a murine 
system [5]. We have been developing VLPs as vaccine 
candidates for RSV with the goal of eliminating many 
of the problems that have been associated with more 
classical approaches to RSV vaccine development. VLPs 
are virus-sized particles released from cells expressing 
the major structural proteins of a virus but in the absence 
of a viral genome. VLPs, therefore, do not contain a 
genome and are thus noninfectious and likely safer than 
infectious, attenuated viruses or live virus vectored 
vaccine candidates. Conformation of proteins in VLPs 
can also be more easily manipulated than virion associated 
proteins since cell entry functions need not be maintained. 
Immune responses to an antigen are considerably 
improved if the antigen is associated with a virus-sized 
particle in an ordered, repetitive array [6]. VLP associated 
glycoproteins are expressed in an ordered array and retain 
authentic epitopes since they do not require chemical 
treatment with the accompanying conformational changes 
necessary for inactivated virus vaccine preparation. It has 
also been found that VLPs stimulate robust humoral and 
cellular immune responses without adjuvant addition, 
a complicating requirement for soluble protein vaccine 
candidates. 
We have previously shown that VLPs containing the 
wild type RSV F protein stimulated durable, neutralizing 
antibody responses, protection from RSV challenge, and 
memory B cell responses in a murine system, in contrast to 
RSV infection [5]. Furthermore, we showed that induction 
of B cell memory depended upon the conformation of the 
F protein [7]. However, the neutralizing antibody titers 
induced by these VLPs were not as high as that deemed 
necessary for protection in humans although titers were 
much higher than those induced by RSV infection. While 
the wild type F protein in VLPs contained the pre-fusion 
specific epitope [7], the instability of the wild type F 
pre-fusion form likely resulted in the conversion of the 
pre-fusion to the post-fusion form during immunization. 
However, we found that incorporation of the stabilized 
pre-fusion F protein into VLPs was able to increase the 
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neutralizing antibody titers, after a single injection of 
VLPs, by 5-6 fold compared to titers induced by wild type 
F containing VLPs and to levels well above the minimal 
titers necessary for protective antibodies [5]. 
VLPs are increasingly being considered as vaccine 
candidates for a variety of human and animal pathogens. 
Our results demonstrate that the conformation of antigens 
in VLPs is of critical importance for optimal stimulation of 
protective as well as durable immune responses.
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